Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-03-14
2006-03-14
Low, Christopher S. F. (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S380000, C530S381000, C530S350000, C930S010000, C930S100000, C435S069100, C435S069600
Reexamination Certificate
active
07012132
ABSTRACT:
Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.
REFERENCES:
patent: 4757006 (1988-07-01), Toole
patent: 4868112 (1989-09-01), Toole
patent: 5364771 (1994-11-01), Lollar
patent: 5563045 (1996-10-01), Pittman et al.
patent: 5663060 (1997-09-01), Lollar et al.
patent: 0 182 448 (1986-05-01), None
patent: 0 306 968 (1988-09-01), None
patent: WO 91/07438 (1990-11-01), None
patent: WO 94/11503 (1994-05-01), None
patent: WO 97/03191 (1997-01-01), None
patent: WO 97/03193 (1997-01-01), None
patent: WO 99/46274 (1999-09-01), None
Supplementary European Search Report, Sep. 21, 2004 EP 01 91 0853.
Pittman, DD et al. (1993) “Biochemical Immunological and in vivo Functional Characterization of B-Domain Deleted Factor VIII”;Blood81(11):2925-2935.
Lind et al. (1995) “Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization”;Eur. J. Biochem232(1):19-27.
Bihoreau, N et al. (1991) “Structural and Functional Characterization of Factor VIII-ΔII, a new recombinant Factor VIII lacking most of the B-domain”;Biochem. J.277—23-31.
Muelien, P (1988) “A new recombinant procoagulant protein derived from the cDNA encoding Human Factor VIII”;Protein Engineering2(4):301-306.
Sarver, N et al. (1987) “Stable Expression of Recombinant Factor VIII Molecules Using a Bovine Papillomavirus Vector”;DNA6(6):553-564.
Data Base Swiss-Prot Fa8_PIG, Oct. 1, 1989 “Coagulation Factor VIII Precursor”; Database Accession No. P12263.
Church, et al. “Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins”; (1984)Proc. Natl. Acad. Sci. USA81:6934.
Dominguez, O. et al. “Gene walking by unpredictably primed PCR”; (1994)Nucleic Acids Res.22:3247-3248.
Eaton, D.L. et al. “Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule” (1986)Biochemistry25(26):8343-8347.
Fulcher, C.A. et al. “Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments”; (1985)Proc. Natl. Acad. Sci. USA82:7728-7732.
Healy, J.F. et al. “The cDNA and Derived Amino Acid Sequence of Porcine Factor VIII”; (1996)Blood88:4209-4214.
Gitcher, J. et al. Characterization of the human factor VIII gene; (1984)Nature312:326-330.
Healey, J.F., Lubin, I.M., Lollar, P., EMBL/GENBANK/DDBJ databanks, Aug. 1996.
Lubin, et al. “Elimination of a Major Inhibitor Epitope in Factor VIII”; (1994)J. Biol. Chem.269:8639-8641.
Nakai, H. et al. “Properties of Affinity Purified Anti-factor VIII Antibodies from Patients with Factor VIII Inhibitors”; (1994)Blood84:224a.
Ochman, H. et al. “Inverse Polymerase Chain Reaction”; (1990)Biotech.N.Y. 8:759-760.
Parker, J.D. et al. “Targeted gene-walking polymerase chain reaction”; (1991)Nucleic Acids. Res.19:3055-3060.
Parker, J.D. et al. “The Oligomer Extension ‘Hot Blot’; A Rapid Alternative to Southern Blots for Analyzing Polymerase Chain Reaction Products”; (1991)Biotechniques10:94-101.
Sarkar, G. et al. “Restriction-site PCR: A Direct Method of Unknown Sequence Retrieval Adjacent to a Known Locus by Using Universal Primers”; (1993)PCR Meth. Appl.2:318-322.
Scandella, D. et al. “Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed inEscherichia coli”; (1988)Proc. Natl. Acad. Sci. USA85:6152-6156.
Scandella, D. et al. “Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization” (1989)Blood74:1618-1626.
Scandella, D. et al. “Some Factor VIII Inhibitor Antibodies Recognize a Common Epitope Corresponding to C2 Domain Amino Acids 2248 Through 2312, Which Overlap a Phospholipid-Binding Site”; (1995)Blood86:1811-1819.
Scandella, D. et al. “A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2”; (1993)Blood82(6):1767-1775.
Siebert, P.D. et al. “An improved PCR method for walking in unclosed genomic DNA”; (1995)Nucleic Acids Res.23:1087-1088.
Toole, et al. “Molecular cloning of a cDNA encoding human antihaemophilic factor”; (1984)Nature312:342-347.
Toole, et al. “A large region (≈ 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity”; (1986)Proc. Natl. Acad. Sci. USA83:5939-5942.
Verma et al. Gene Therapy—promises, problems and prospects, (Sep. 1997),Nature389:239-242.
Emory University
Greenlee Winner and Sullivan
Low Christopher S. F.
Schnizer Holly
LandOfFree
Modified factor VIII does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified factor VIII, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified factor VIII will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3577580